Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
QURE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.73 - $19.18
Previous CloseN/A
Volume1.49M
Average Volume (3M)1.92M
Market Cap
$766.81M
Enterprise Value$996.00M
Total Cash (Recent Filing)-$336.99K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.75
Next Earnings
May 13, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.92
Shares Outstanding54,076,880
10 Day Avg. Volume2,767,954
30 Day Avg. Volume1,920,877
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)27.32
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit38.53
Enterprise Value/Ebitda-6.20
Forecast
1Y Price Target
$35.00Price Target Upside146.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
uniQure News
PremiumCompany Announcements
uniQure Amends CEO Employment Agreement
PremiumCompany Announcements
uniQure Reports 2024 Financial Results and Progress
---
Bulls Say, Bears Say
Bulls Say
Financial HealthUniQure's healthy balance sheet and cash runway into the second half of 2027, along with multiple clinical data readouts expected, suggest the company is significantly undervalued.
Pipeline DevelopmentPrograms for epilepsy, Fabry, and ALS are progressing in the clinic, suggesting a robust pipeline beyond AMT-130.
Regulatory ApprovalThe FDA granted Breakthrough Therapy designation to uniQure's lead gene therapy program AMT-130 for the treatment of Huntington’s disease, supporting an accelerated pathway to approval.
Bears Say
Market CompetitionHuntington's is an area with high unmet need, as there are no disease-modifying therapies currently approved, which poses challenges in market acceptance.
---
Ownership Overview
2.74% Insiders
8.43% Mutual Funds
0.89% Other Institutional Investors
81.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $3.73 and its highest was $19.18 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $766.81M.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is May 13, 2025 which is in 16 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Feb 27, 2025. The company reported -$1.49 earnings per share for the quarter, missing the consensus estimate of -$0.653 by -$0.837.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -1.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 54,076,880 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$1.49 in its last earnings report, missing expectations of -$0.653. Following the earnings report the stock price went up 3.428%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in QURE
---
uniQure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.00 (146.83% Upside)
$35.00 (146.83% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 122.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.1%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
212.71%
12-Months-Change
Fundamentals
Return on Equity
-238.46%
Trailing 12-Months
Asset Growth
-33.08%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
---
QURE Stock 12 Month Forecast
Average Price Target
$35.00
▲(146.83% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Sarepta Therapeutics
―
Bluebird Bio
―
Adverum Biotechnologies
―
Crispr Therapeutics AG
―
Best Analysts Covering QURE
1 Year
1 Year Success Rate
11/22 ratings generated profit
1 Year Average Return
+18.99%
reiterated a buy rating 6 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +18.99% per trade.
---